<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7135139/results/search/disease/results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
  <result pre="virus [2]. A response has come from China to the" exact="respiratory" post="disease caused by the new coronavirus (SARS-CoV-2) that emerged"/>
  <result pre="[2]. A response has come from China to the respiratory" exact="disease" post="caused by the new coronavirus (SARS-CoV-2) that emerged in"/>
  <result pre="on the efficacy of this drug in patients with SARS-CoV-2-related" exact="pneumonia" post="(named COVID-19) at different levels of severity [4,5]. Thus,"/>
  <result pre="of exacerbation of pneumonia, duration of symptoms and delay of" exact="viral" post="clearance, all in the absence of severe side effects"/>
  <result pre="of symptoms and delay of viral clearance, all in the" exact="absence of" post="severe side effects [4,5]. This has led in China"/>
  <result pre="in the recommendations regarding the prevention and treatment of COVID-19" exact="pneumonia" post="[4,6]. There is a strong rationality for the use"/>
  <result pre="a strong rationality for the use of chloroquine to treat" exact="infections" post="with intracellular micro-organisms. Thus, malaria has been treated for"/>
  <result pre="use of chloroquine to treat infections with intracellular micro-organisms. Thus," exact="malaria" post="has been treated for several decades with this molecule"/>
  <result pre="team has used hydroxychloroquine for the first time for intracellular" exact="bacterial infections" post="since 30 years to treat the intracellular bacterium Coxiella"/>
  <result pre="has used hydroxychloroquine for the first time for intracellular bacterial" exact="infections" post="since 30 years to treat the intracellular bacterium Coxiella"/>
  <result pre="to treat the intracellular bacterium Coxiella burnetii, the agent of" exact="Q fever," post="for which we have shown in vitro and then"/>
  <result pre="the activity of hydroxychloroquine on Tropheryma whipplei, the agent of" exact="Whipple's disease," post="which is another intracellular bacterium for which hydroxychloroquine has"/>
  <result pre="has treated ~4000 cases of C. burnetii or T. whipplei" exact="infections" post="over 30 years (personal data). Regarding viruses, for reasons"/>
  <result pre="this molecule, including against coronaviruses among which is the severe" exact="acute" post="respiratory syndrome (SARS)-associated coronavirus [1,12,13] (Table 1 ). We"/>
  <result pre="molecule, including against coronaviruses among which is the severe acute" exact="respiratory" post="syndrome (SARS)-associated coronavirus [1,12,13] (Table 1 ). We previously"/>
  <result pre="including against coronaviruses among which is the severe acute respiratory" exact="syndrome" post="(SARS)-associated coronavirus [1,12,13] (Table 1 ). We previously emphasised"/>
  <result pre="We previously emphasised interest in chloroquine for the treatment of" exact="viral" post="infections in this journal [1], predicting its use in"/>
  <result pre="previously emphasised interest in chloroquine for the treatment of viral" exact="infections" post="in this journal [1], predicting its use in viral"/>
  <result pre="viral infections in this journal [1], predicting its use in" exact="viral" post="infections lacking drugs. Following the discovery in China of"/>
  <result pre="infections in this journal [1], predicting its use in viral" exact="infections" post="lacking drugs. Following the discovery in China of the"/>
  <result pre="addition of this drug was carried out before or after" exact="viral infection" post="of the cells) [3], we awaited with great interest"/>
  <result pre="of this drug was carried out before or after viral" exact="infection" post="of the cells) [3], we awaited with great interest"/>
  <result pre="length of hospital stay and improve the evolution of COVID-19" exact="pneumonia" post="[4,6], leading to recommend the administration of 500 mg"/>
  <result pre="reduced for the intranasal route (but not the intraperitoneal route)" exact="viral" post="lung titres from mean ± S.D. of 5.4 ±"/>
  <result pre="EC50 = 28 ± 27 μM [19] Chloroquine HCoV-229E Human" exact="epithelial" post="lung cells (L132) Chloroquine at concentrations of 10 μM"/>
  <result pre="Chloroquine HCoV-OC43 HRT-18 cells EC50 = 0.306 ± 0.0091 μM" exact="Newborn" post="C57BL/6 mice; chloroquine administration transplacentally and via maternal milk"/>
  <result pre="1 and 0 mg/kg body weight, respectively [21] Chloroquine Feline" exact="infectious" post="peritonitis virus (FIPV) Felis catus whole fetus-4 cells FIPV"/>
  <result pre="and 0 mg/kg body weight, respectively [21] Chloroquine Feline infectious" exact="peritonitis" post="virus (FIPV) Felis catus whole fetus-4 cells FIPV replication"/>
  <result pre="E6 cells EC50 = 1.13 μM CCID50, 50% cell culture" exact="infectious" post="dose; CoV, coronavirus; EC50, 50% effective concentration (mean ±"/>
  <result pre="GFP, green fluorescent protein; HCoV, human coronavirus; MERS, Middle East" exact="respiratory" post="syndrome; SARS, severe acute respiratory syndrome; S.D., standard deviation."/>
  <result pre="HCoV, human coronavirus; MERS, Middle East respiratory syndrome; SARS, severe" exact="acute" post="respiratory syndrome; S.D., standard deviation. aSee also [1] (Table"/>
  <result pre="human coronavirus; MERS, Middle East respiratory syndrome; SARS, severe acute" exact="respiratory" post="syndrome; S.D., standard deviation. aSee also [1] (Table 1)"/>
  <result pre="chloroquine and its hydroxyl analogue to face bacterial, fungal and" exact="viral" post="infections in the 21st centuryInt J Antimicrob Agents30200729730810.1016/j.ijantimicag.2007.05.01517629679 2BosseboeufE.AubryM.NhanT.de"/>
  <result pre="and its hydroxyl analogue to face bacterial, fungal and viral" exact="infections" post="in the 21st centuryInt J Antimicrob Agents30200729730810.1016/j.ijantimicag.2007.05.01517629679 2BosseboeufE.AubryM.NhanT.de PinaJ.J.RolainJ.M.RaoultD.Azithromycin"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci Trends2020 Feb 1910.5582/bst.2020.01047[Epub ahead of print]"/>
  <result pre="PneumoniaExpert consensus on chloroquine phosphate for the treatment of novel" exact="coronavirus pneumonia" post="[in Chinese]Zhonghua Jie He He Hu Xi Za Zhi432020E01910.3760/cma.j.issn.1001-0939.2020.001932075365"/>
  <result pre="consensus on chloroquine phosphate for the treatment of novel coronavirus" exact="pneumonia" post="[in Chinese]Zhonghua Jie He He Hu Xi Za Zhi432020E01910.3760/cma.j.issn.1001-0939.2020.001932075365"/>
  <result pre="directions of uses, mechanisms of actions and toxic manifestations from" exact="malaria" post="to multifarious diseasesJ Antimicrob Chemother7020151608162110.1093/jac/dkv01825693996 8RaoultD.DrancourtM.VestrisG.Bactericidal effect of doxycycline"/>
  <result pre="Coxiella burnetii in P388D1 cellsAntimicrob Agents Chemother3419901512151410.1128/aac.34.8.15122221859 9RaoultD.HoupikianP.Tissot DupontH.RissJ.M.Arditi-DjianeJ.BrouquiP.Treatment of" exact="Q fever" post="endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin"/>
  <result pre="diseaseN Engl J Med3562007556610.1056/NEJMra06247717202456 12KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquineBiochem Biophys Res Commun323200426426810.1016/j.bbrc.2004.08.08515351731 13SavarinoA.Di"/>
  <result pre="Engl J Med3562007556610.1056/NEJMra06247717202456 12KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquineBiochem Biophys Res Commun323200426426810.1016/j.bbrc.2004.08.08515351731 13SavarinoA.Di TraniL.DonatelliI.CaudaR.CassoneA.New"/>
  <result pre="J Med3562007556610.1056/NEJMra06247717202456 12KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquineBiochem Biophys Res Commun323200426426810.1016/j.bbrc.2004.08.08515351731 13SavarinoA.Di TraniL.DonatelliI.CaudaR.CassoneA.New insights"/>
  <result pre="outcomeJ Antimicrob Chemother69201421922710.1093/jac/dkt31023946319 16VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS" exact="coronavirus infection" post="and spreadVirol J220056910.1186/1743-422X-2-6916115318 17BarnardD.L.DayC.W.BaileyK.HeinerM.MontgomeryR.LauridsenL.Evaluation of immunomodulators, interferons and known"/>
  <result pre="Antimicrob Chemother69201421922710.1093/jac/dkt31023946319 16VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J220056910.1186/1743-422X-2-6916115318 17BarnardD.L.DayC.W.BaileyK.HeinerM.MontgomeryR.LauridsenL.Evaluation of immunomodulators, interferons and known"/>
  <result pre="and antiviral activitiesJ Med Chem4920062845284910.1021/jm060185616640347 19KonoM.TatsumiK.ImaiA.M.SaitoK.KuriyamaT.ShirasawaH.Inhibition of human coronavirus 229E" exact="infection" post="in human epithelial lung cells (L132) by chloroquine: involvement"/>
  <result pre="Med Chem4920062845284910.1021/jm060185616640347 19KonoM.TatsumiK.ImaiA.M.SaitoK.KuriyamaT.ShirasawaH.Inhibition of human coronavirus 229E infection in human" exact="epithelial" post="lung cells (L132) by chloroquine: involvement of p38 MAPK"/>
  <result pre="Res77200815015210.1016/j.antiviral.2007.10.01118055026 20KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.Antiviral activity of chloroquine against human coronavirus OC43" exact="infection" post="in newborn miceAntimicrob Agents Chemother5320093416342110.1128/AAC.01509-0819506054 21TakanoT.KatohY.DokiT.HohdatsuT.Effect of chloroquine on"/>
  <result pre="in newborn miceAntimicrob Agents Chemother5320093416342110.1128/AAC.01509-0819506054 21TakanoT.KatohY.DokiT.HohdatsuT.Effect of chloroquine on feline" exact="infectious" post="peritonitis virus infection in vitro and in vivoAntiviral Res99201310010710.1016/j.antiviral.2013.04.016723648708"/>
  <result pre="newborn miceAntimicrob Agents Chemother5320093416342110.1128/AAC.01509-0819506054 21TakanoT.KatohY.DokiT.HohdatsuT.Effect of chloroquine on feline infectious" exact="peritonitis" post="virus infection in vitro and in vivoAntiviral Res99201310010710.1016/j.antiviral.2013.04.016723648708 22de"/>
  <result pre="miceAntimicrob Agents Chemother5320093416342110.1128/AAC.01509-0819506054 21TakanoT.KatohY.DokiT.HohdatsuT.Effect of chloroquine on feline infectious peritonitis" exact="virus infection" post="in vitro and in vivoAntiviral Res99201310010710.1016/j.antiviral.2013.04.016723648708 22de WildeA.H.JochmansD.PosthumaC.C.Zevenhoven-DobbeJ.C.van NieuwkoopS.BestebroerT.M.Screening"/>
  <result pre="Agents Chemother5320093416342110.1128/AAC.01509-0819506054 21TakanoT.KatohY.DokiT.HohdatsuT.Effect of chloroquine on feline infectious peritonitis virus" exact="infection" post="in vitro and in vivoAntiviral Res99201310010710.1016/j.antiviral.2013.04.016723648708 22de WildeA.H.JochmansD.PosthumaC.C.Zevenhoven-DobbeJ.C.van NieuwkoopS.BestebroerT.M.Screening"/>
  <result pre="FDA-approved compound library identifies four small-molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell cultureAntimicrob Agents Chemother5820144875488410.1128/AAC.03011-1424841269 Funding:"/>
  <result pre="compound library identifies four small-molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell cultureAntimicrob Agents Chemother5820144875488410.1128/AAC.03011-1424841269 Funding: This"/>
  <result pre="program managed by the National Agency for Research (ANR) [Méditerranée" exact="Infection" post="10-IAHU-03]. The funding sources had no role in the"/>
 </snippets>
</snippetsTree>
